Laure Ricard

Laure Ricard

Auto-generated profile, based on publicly available information

Laure Ricard

Sorbonne Université, AP‐HP, Hôpital Saint‐Antoine, Service d'Hématologie Clinique et Thérapie Cellulaire Paris France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2022 in Blood
Verified
Journal Article
Closed access
PDF file
MWMatthew R. Wilson
Matthew R. Wilson
TEToby Eyre
Toby Eyre
AKAmy A. Kirkwood
Amy A. Kirkwood
NDNicole Wong Doo
Nicole Wong Doo
CSCarole Soussain
Carole Soussain
PMPamela McKay
Pamela McKay
Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We conducted a retrospective, international analysis of 1384 patients receiving HD-MTX CNS prophylaxis either intercalated (i-HD-MTX) (n = 749) or at the end (n = 635) of R-CHOP/R-CHOP-like therapy (EOT). There were 78 CNS relapses (3-year rate 5.7%), with no difference between i-HD-MTX and EOT: 5.7% vs 5.8%, P = .98; 3-year difference: 0.04% (−2.0% to 3.1%). Conclusions were unchanged on adjusting for baseline prognostic factors or on 6-month landmark analysis (n = 1253). In patients with a high CNS international prognostic index (n = 600), the 3-year CNS relapse rate was 9.1%, with no difference between i-HD-MTX and EOT. On multivariable analysis, increasing age and renal/adrenal involvement were the only independent risk factors for CNS relapse. Concurrent intrathecal prophylaxis was not associated with a reduction in CNS relapse. R-CHOP delays of ≥7 days were significantly increased with i-HD-MTX vs EOT, with 308 of 1573 (19.6%) i-HD-MTX treatments resulting in a delay to subsequent R-CHOP (median 8 days). Increased risk of delay occurred in older patients when delivery was later than day 10 in the R-CHOP cycle. In summary, we found no evidence that EOT delivery increases CNS relapse risk vs i-HD-MTX. Findings in high-risk subgroups were unchanged. Rates of CNS relapse in this HD-MTX-treated cohort were similar to comparable cohorts receiving infrequent CNS prophylaxis. If HD-MTX is still considered for certain high-risk patients, delivery could be deferred until R-CHOP completion.

21 April 2022 in Blood
Verified
Journal Article
Open access
PDF file
APAdrien Picod
Adrien Picod
JRJean-Michel Rebibou
Jean-Michel Rebibou
ADAntoine Dossier
Antoine Dossier
BCBérengère Cador
Bérengère Cador
DRDavid Ribes
David Ribes
PCPaul Coppo*
Paul Coppo*

28 January 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
NSNicolas Stocker
Nicolas Stocker
BGBéatrice Gaugler
Béatrice Gaugler
LRLaure Ricard
Laure Ricard
FVFrédéric de Vassoigne
Frédéric de Vassoigne
ZMZora Marjanovic
Zora Marjanovic
FMFlorent Malard
Florent Malard
Background: Daratumumab (Dara), an anti‐CD38 monoclonal antibody, has an immunologic mechanism of action through targeting of CD38 expressing immune cells in patients with multiple myeloma (MM). Furthermore, it was recently shown that CD38 upregulation in tumors, is a major mechanism of acquired resistance to antiprogrammed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1). Therefore, we decided to evaluate the immunomodulatory effects of CD38 blockade by Dara on the PD‐L1 expressing immune cells.Methods: We analyzed CD38 and PD‐L1 expression on immune cells at different time points in 18 newly diagnosed MM receiving bortezomib, lenalidomide and dexamethasone, with or without Dara.Results: We first confirmed that CD38 is widely expressed on immune cells, with the strongest expression on plasmacytoid dendritic cells (pDC). Furthermore, Dara induces a strong depletion of pDC in addition to the well‐known rapid depletion of natural killer cells. Finally, we found that PD‐L1 expression on antigen‐presenting cells (APC) increases with MM treatment in patients that did not received Dara, while addition of Dara prevents this increase.Conclusion: Overall, our results suggest new mechanisms of action of Dara through depletion of pDC and prevention of PD‐L1 upregulation expression on APC. Our finding provides new evidences for development of therapeutic strategies targeting both CD38 and PD‐L1/PD‐1 pathway in patients with MM.

27 June 2022 in Clinical and Experimental Immunology
Verified
Journal Article
Closed access
PDF file
LRLaure Ricard
Laure Ricard
DEDéborah Eshagh
Déborah Eshagh
LSLama Siblany
Lama Siblany
FVFrédéric de Vassoigne
Frédéric de Vassoigne
FMFlorent Malard
Florent Malard
AMArsene Mekinian
Arsene Mekinian
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis, microangiopathy and autoantibodies. We previously reported that circulating follicular helper T (cTfh) cells are increased in SSc and induce plasmablast differentiation. However, mechanisms leading to cTfh cell expansion and activation in SSc remain to be established. Tfh cells require IL-12 for their expansion and differentiation. 6-sulfo LacNAc monocytes (slanMo), a subset of monocytes, have a higher capacity to produce IL-12 and to induce CD4 + T cell proliferation in comparison with dendritic cells (DC) or classical monocytes. The aim of this study was to perform a quantitative and functional analysis of monocytes and DC and to correlate them with cTfh cell expansion and clinical manifestations in SSc. Using flow cytometry, we analyzed different monocyte subsets including slanMo and DC from 36 SSc patients and 26 healthy controls (HC). In vitro culture experiments of sorted slanMo were performed for functional analysis and cytokine production. We observed that slanMo, intermediate and non-classical monocytes were increased in SSc in comparison with HC. Furthermore, the increase in slanMo cells was more potent in patients with diffuse SSc. We observed a significant positive correlation between slanMo and cTfh cell levels in SSc patients but not in HC. Other monocyte subsets did not correlate with cTfh cell expansion. In addition, we observed that in vitro, slanMo cells from SSc patients produced less IL-12 than slanMo from HC. SlanMo are increased in SSc and may participate in the activation of cTfh cells in SSc.

9 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MDMarion Detroit
Marion Detroit
MCMathis Collier
Mathis Collier
NBNathanaël Beeker
Nathanaël Beeker
LWLise Willems
Lise Willems
JDJustine Decroocq
Justine Decroocq
JZJeremie Zerbit
Jeremie Zerbit
Immunotherapy (IT) is a major therapeutic strategy for lymphoma, significantly improving patient prognosis. IT remains ineffective for a significant number of patients, however, and exposes them to specific toxicities. The identification predictive factors around efficacy and toxicity would allow better targeting of patients with a higher ratio of benefit to risk. PRONOSTIM is a multicenter and retrospective study using the Clinical Data Warehouse (CDW) of the Greater Paris University Hospitals network. Adult patients with Hodgkin lymphoma or diffuse large-cell B lymphoma treated with immune checkpoint inhibitors or CAR T (Chimeric antigen receptor T) cells between 2017 and 2022 were included. Analysis of covariates influencing progression-free survival (PFS) or the occurrence of grade ≥3 toxicity was performed. In total, 249 patients were included. From this study, already known predictors for response or toxicity of CAR T cells such as age, elevated lactate dehydrogenase, and elevated C-Reactive Protein at the time of infusion were confirmed. In addition, male gender, low hemoglobin, and hypo- or hyperkalemia were demonstrated to be potential predictive factors for progression after CAR T cell therapy. These findings prove the attractiveness of CDW in generating real-world data, and show its essential contribution to identifying new predictors for decision support before starting IT.

27 August 2024 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
LRLaure Ricard
Laure Ricard
FCFabienne Charbit‐Henrion
Fabienne Charbit‐Henrion
ACAlice Courties
Alice Courties
MMMohamad Mohty
Mohamad Mohty
OLOllivier Legrand
Ollivier Legrand
FMFlorent Malard
Florent Malard